ClinicalTrials.gg
CompletedNCT01644500AWARD-CHN1Updated Sep 18, 2019Results posted

A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus

A Phase 3 interventional study of Dulaglutide and Glimepiride in Type 2 Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 30 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-18.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
737
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
10th of 54
737 · median 159
Started
2012
with 7 others
Phase 3
22 of 54
1 open now
Registered
26th of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 10th largest by enrollment, is one of 8 that started in 2012, is one of 22 in phase 3, and was the 26th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to examine if once-weekly dulaglutide is efficient and safe compared to glimepiride in participants with type 2 diabetes mellitus who have inadequate glycemic control with oral antihyperglycemic medication (OAM) or are OAM-naïve.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes mellitus
  • OAM-naïve or have been taking OAM monotherapy for at least 3 months
  • Glycosylated () value of ≥7.0% to ≤10.5% for OAM-naïve participants or ≥6.5% to ≤10.0% for participants taking OAM monotherapy
  • Adult men or adult non-pregnant, non-breastfeeding women
  • Stable weight (±5%) ≥3 months prior to screening
  • (BMI) of ≥19.0 to ≤35.0 kilograms per square meter (kg/m\^2)

Exclusion criteria

Exclusion Criteria:

  • Have type 1 diabetes mellitus
  • Have previously been treated with a glucagon-like peptide-1 (GLP-1) receptor agonist, GLP-1 analog, or any other incretin mimetic during the 3 months before screening
  • Are currently taking dipeptidylpeptidase-IV (DPP-IV) inhibitor and thiazolidinediones (TZD) during the 3 months before screening
  • Have gastric emptying abnormality
  • Have cardiac disorder defined as unstable angina, myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary intervention, heart failure, arrhythmia, , or stroke
  • Have poorly controlled hypertension (systolic blood pressure above 160 millimeters of mercury [mmHg] or diastolic blood pressure above 95 mmHg)
  • Have impaired liver function
  • Have impaired kidney function
  • Have history of chronic pancreatitis or acute pancreatitis
  • Have a serum calcitonin ≥20 picogram/milliliter (pg/mL)
  • Have a personal or family history of medullary C-cell hyperplasia, focal hyperplasia, carcinoma or multiple endocrine neoplasia type 2 (MEN 2)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
737 participants (actual)

Study arms

  • Experimental
    1.5 mg Dulaglutide

    1.5 milligrams (mg) dulaglutide administered as one subcutaneous (SC) injection once-weekly plus one to three capsules of placebo each day for blinding purposes for up to 26 weeks.

    Drug: Dulaglutide · Drug: Placebo as Capsules

  • Experimental
    0.75 mg Dulaglutide

    0.75 mg dulaglutide administered as one SC injection once-weekly plus one to three capsules of placebo each day for blinding purposes for up to 26 weeks.

    Drug: Dulaglutide · Drug: Placebo as Capsules

  • Active comparator
    Glimepiride

    1 to 3 mg per day (mg/day) glimepiride administered orally as one to three capsules per day plus one SC injection of placebo once-weekly for blinding purposes for up to 26 weeks.

    Drug: Glimepiride · Drug: Placebo as SC Injection

Interventions

  • Administered SC

    Also known as: LY2189265

  • Administered orally

  • DrugPlacebo as Capsules

    Placebo for glimepiride is administered orally as one to three capsules daily.

  • DrugPlacebo as SC Injection

    Placebo for dulaglutide is administered as one SC injection.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in HbA1c at 26 Weeks

    HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline HbA1c as covariate; and participant as a random effect.

    Time frame: Baseline, 26 Weeks

Secondary outcomes

  1. Percentage of Participants Attaining HbA1c of <7% or ≤6.5% at 26 Weeks

    Percentages of participants who achieved HbA1c levels of \<7% or ≤6.5% were analyzed using a logistic regression model, controlling for treatment, pre-treatment, baseline HbA1c and country.

    Time frame: 26 Weeks

  2. Change From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks

    FBG is a test to determine how much glucose (sugar) is in a blood sample after an overnight fast. FBG was measured by a central laboratory. LS means were calculated using MMRM analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline FBG as covariate; and participant as a random effect.

    Time frame: Baseline, 26 Weeks

  3. Change From Baseline in 7-point Self-monitored Blood Glucose (SMBG) Profiles at 26 Weeks

    Change from baseline in mean daily blood glucose (BG) values were measured with a 7-point SMBG profile. Participants recorded their 7-point SMBG profiles on 2 separate, non-consecutive days during the 2-week period immediately before randomization, Week 8, Week 16, and Week 26 (or the Early Discontinuation Visit). The 7-point SMBG profile consisted of pre-prandial BG measures before the morning (fasting), midday, and evening meals; BG measures 2 hours after the start (post-prandial) of the morning, midday, and evening meals; and BG measures at bedtime. Mean at 26 weeks was assessed in all treatment groups. LS means were calculated using MMRM analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline body weight as covariate; and participant as a random effect.

    Time frame: Baseline, 26 Weeks

  4. Rate of Hypoglycemic Episodes

    Hypoglycemic episodes are defined as events that are associated with reported signs and symptoms of hypoglycemia and/or documented BG concentrations of ≤70 milligrams per deciliter (mg/dL) (≤3.9 mmol/L). A severe hypoglycemic episode was defined as any hypoglycemic event for which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs between bedtime and waking. Log mean rates of total hypoglycemia (per 30 days per participant) are presented and were calculated from negative binomial regression model. The model included country/region, prior medication group, treatment, visit, and treatment-by-visit interaction. The logarithm of days between visits was adjusted as an offset to account for possible unequal duration between visits and between participants.

    Time frame: Baseline through 26 Weeks

  5. Number of Participants With Self-Reported Hypoglycemic Episodes

    The overall number of participants with self-reported hypoglycemic episodes is presented.

    Time frame: Baseline through 26 Weeks

  6. Change From Baseline in Homeostasis Model Assessment 2 Steady-state Beta (β) - Cell Function (HOMA2-%B) at 26 Weeks

    Change from baseline in HOMA2-%B was assessed by using the homeostasis model assessment (HOMA) to quantify β-cell function. HOMA2-%B is a computer model that uses FBG, insulin, and C-peptide concentrations to estimate steady state β-cell function (%B) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. LS means were calculated using an analysis of covariance (ANCOVA) model with country, baseline, pre-treatment, and treatment as fixed effects.

    Time frame: Baseline, up to 26 Weeks

  7. Change From Baseline in Homeostasis Model Assessment 2 Insulin Sensitivity - Cell Function (HOMA2-%S) at 26 Weeks

    Change from baseline in HOMA2-%S was assessed by using the HOMA to quantify insulin sensitivity. HOMA2-%S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state insulin sensitivity (%S) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. LS means were calculated using an ANCOVA model with country, baseline, pre-treatment, and treatment as fixed effects.

    Time frame: Baseline, up to 26 Weeks

  8. Change From Baseline in Pancreatic Enzymes at 26 Weeks

    Amylase (total and pancreas-derived) and lipase concentrations were measured.

    Time frame: Baseline, 26 Weeks

  9. Change From Baseline in Serum Calcitonin at 26 Weeks

    Time frame: Baseline, 26 Weeks

  10. Change From Baseline in Sitting Blood Pressure at 26 Weeks

    Sitting systolic blood pressure (SBP) and sitting diastolic blood pressure (DBP) were measured. LS means were calculated using MMRM analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline blood pressure as covariate; and participant as a random effect.

    Time frame: Baseline, 26 Weeks

  11. Change From Baseline in Sitting Pulse Rate at 26 Weeks

    LS means were calculated using MMRM analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline pulse rate as covariate; and participant as a random effect.

    Time frame: Baseline, 26 Weeks

  12. Change From Baseline in Electrocardiogram (ECG) Parameters, Fridericia Corrected QT (QTcF) Interval and P-R Wave (PR) Interval at 26 Weeks

    The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTcF = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and R-R wave (RR), which is the interval between two R waves. PR is the interval between the P wave and the ventricular depolarization wave (QRS) complex.

    Time frame: Baseline, 26 Weeks

  13. Change From Baseline in Heart Rate From ECG at 26 Weeks

    Time frame: Baseline, 26 Weeks

  14. Change From Baseline in Body Weight at 26 Weeks

    LS means were calculated using MMRM analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline body weight as covariate; and participant as a random effect.

    Time frame: Baseline, 26 Weeks

  15. Change From Baseline in Body Mass Index (BMI) at 26 Weeks

    BMI is an estimate of body fat based on body weight divided by height squared. LS means were calculated using MMRM analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline body weight as covariate; and participant as a random effect.

    Time frame: Baseline, 26 Weeks

  16. Percentage of Participants Developing Antibodies to Dulaglutide

    Dulaglutide anti-drug antibodies (ADA) were assessed at baseline and 26 weeks. A participant was considered to have treatment-emergent dulaglutide ADA if the participant had at least 1 titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.

    Time frame: Baseline through 26 Weeks

  17. Number of Participants With Adjudicated Cardiovascular Events

    Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs that were adjudicated included myocardial infarction; hospitalization for unstable angina; hospitalization for heart failure; coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention); and cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious AEs regardless of causality, is located in the Reported Adverse Events module.

    Time frame: Baseline through 26 Weeks

  18. Number of Participants With Adjudicated Pancreatitis

    The number of adjudicated (by an independent committee of expert physicians) pancreatic events is summarized at 26 weeks. A summary of serious and other non-serious AEs regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 26 Weeks

  19. European Quality of Life Questionnaire-5 Dimensions (EQ-5D) Health State Score Responses at 26 Weeks

    The EQ-5D questionnaire is a widely used, generic questionnaire that assesses 5 dimensions associated with quality of life (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 possible levels of response: no problem, some problem, and extreme problem. Additional categories of response include ambiguous and missing. The number of participants per each of the 5 response categories is summarized for each of the 5 dimensions.

    Time frame: Week 26

  20. Visual Analog Scale (VAS) Score at 26 Weeks

    The EQ-5D questionnaire is a widely used, generic questionnaire that assesses health-related quality of life and consists of a 100-milliliter (mm) visual analog scale (VAS) on which the participant rated their perceived health state on that day from 0-mm (worst imaginable health state) to 100-mm (best imaginable health state).

    Time frame: Week 26

07

Results

Posted Dec 17, 2015

Participant flow

Participant flow — Overall Study
Milestone1.5 mg Dulaglutide0.75 mg DulaglutideGlimepiride
Started244248245
Received at least one dose of study drug244248243
Modified intent-to-treat population239239242
Completed222224230
Not completed222415
Withdrew: Adverse event612
Withdrew: Death010
Withdrew: Lost to follow-up380
Withdrew: Protocol violation110
Withdrew: Withdrawal by subject111212
Withdrew: Physician decision111

Outcome measures

PrimaryChange From Baseline in HbA1c at 26 Weeks

HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline HbA1c as covariate; and participant as a random effect.

Time frame:
Baseline, 26 Weeks
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in HbA1c at 26 Weeks
percentage of HbA1c1.5 mg Dulaglutide0.75 mg DulaglutideGlimepiride
Change From Baseline in HbA1c at 26 Weeks-1.48 ± 0.069-1.22 ± 0.069-0.92 ± 0.069
Statistical analysis
  • 1.5 mg Dulaglutide vs Glimepiride · Mixed Models Analysis · p = <0.001 · Mean difference (net): -0.58 · 95% CI -0.76 to -0.39
  • 0.75 mg Dulaglutide vs Glimepiride · Mixed Models Analysis · p = <0.001 · Mean difference (net): -0.32 · 95% CI -0.50 to -0.13
SecondaryPercentage of Participants Attaining HbA1c of <7% or ≤6.5% at 26 Weeks

Percentages of participants who achieved HbA1c levels of \<7% or ≤6.5% were analyzed using a logistic regression model, controlling for treatment, pre-treatment, baseline HbA1c and country.

Time frame:
26 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants Attaining HbA1c of <7% or ≤6.5% at 26 Weeks
percentage of participants1.5 mg Dulaglutide0.75 mg DulaglutideGlimepiride
HbA1c ≤6.5%59.447.741.3
HbA1c <7.0%74.163.657.4
Statistical analysis
  • 1.5 mg Dulaglutide vs Glimepiride · Fisher Exact · p = <0.001 (Treatment comparison for HbA1c ≤6.5%.) · Odds ratio (or): 2.7 · 05% CI 1.8 to 4.1
  • 0.75 mg Dulaglutide vs Glimepiride · Fisher Exact · p = <0.001 (Treatment comparison for HbA1c ≤6.5%.) · Odds ratio (or): 1.6 · 95% CI 1.0 to 2.3
  • 1.5 mg Dulaglutide vs Glimepiride · Fisher Exact · p = <0.001 (Treatment comparison for HbA1c \<7.0%.) · Odds ratio (or): 2.9 · 95% CI 1.8 to 4.5
  • 0.75 mg Dulaglutide vs Glimepiride · Fisher Exact · p = 0.192 (Treatment comparison for HbA1c \<7.0%.) · Odds ratio (or): 1.6 · 95% CI 1.1 to 2.5
SecondaryChange From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks

FBG is a test to determine how much glucose (sugar) is in a blood sample after an overnight fast. FBG was measured by a central laboratory. LS means were calculated using MMRM analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline FBG as covariate; and participant as a random effect.

Time frame:
Baseline, 26 Weeks
Reported as:
Least squares mean · millimoles per liter (mmol/L)
Change From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks
millimoles per liter (mmol/L)1.5 mg Dulaglutide0.75 mg DulaglutideGlimepiride
Change From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks-2.71 ± 0.135-2.26 ± 0.137-1.89 ± 0.136
Statistical analysis
  • 1.5 mg Dulaglutide vs Glimepiride · Mixed Models Analysis · p = <0.001 · Mean difference (net): -0.83 · 95% CI -1.15 to -0.51
  • 0.75 mg Dulaglutide vs Glimepiride · Mixed Models Analysis · p = 0.022 · Mean difference (net): -0.38 · 95% CI -0.70 to -0.05
SecondaryChange From Baseline in 7-point Self-monitored Blood Glucose (SMBG) Profiles at 26 Weeks

Change from baseline in mean daily blood glucose (BG) values were measured with a 7-point SMBG profile. Participants recorded their 7-point SMBG profiles on 2 separate, non-consecutive days during the 2-week period immediately before randomization, Week 8, Week 16, and Week 26 (or the Early Discontinuation Visit). The 7-point SMBG profile consisted of pre-prandial BG measures before the morning (fasting), midday, and evening meals; BG measures 2 hours after the start (post-prandial) of the morning, midday, and evening meals; and BG measures at bedtime. Mean at 26 weeks was assessed in all treatment groups. LS means were calculated using MMRM analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline body weight as covariate; and participant as a random effect.

Time frame:
Baseline, 26 Weeks
Reported as:
Least squares mean · mmol/L
Change From Baseline in 7-point Self-monitored Blood Glucose (SMBG) Profiles at 26 Weeks
mmol/L1.5 mg Dulaglutide0.75 mg DulaglutideGlimepiride
Morning (fasting)-2.47 ± 0.092-1.91 ± 0.092-1.80 ± 0.091
Morning (2 hours post-prandial) meal-4.56 ± 0.180-3.75 ± 0.181-3.20 ± 0.179
Midday (pre-prandial) meal-3.09 ± 0.151-2.43 ± 0.151-2.37 ± 0.150
Midday (2 hours post-prandial) meal-4.15 ± 0.174-3.40 ± 0.174-2.58 ± 0.173
Evening (pre-prandial) meal-2.36 ± 0.135-1.77 ± 0.136-1.69 ± 0.134
Evening (2 hours post-prandial) meal-3.63 ± 0.164-2.80 ± 0.165-2.35 ± 0.164
Bedtime-3.22 ± 0.152-2.69 ± 0.152-2.03 ± 0.150
Statistical analysis
  • 1.5 mg Dulaglutide vs Glimepiride · Mixed Models Analysis · p = <0.001 (Treatment comparison for morning (fasting).) · Mean difference (net): -0.67 · 95% CI -0.89 to -0.45
  • 0.75 mg Dulaglutide vs Glimepiride · Mixed Models Analysis · p = 0.304 (Treatment comparison for morning (fasting).) · Mean difference (net): -0.12 · 95% CI -0.34 to 0.11
  • 1.5 mg Dulaglutide vs Glimepiride · Mixed Models Analysis · p = <0.001 (Treatment comparison for morning (2 hours post-prandial) meal.) · Mean difference (net): -1.36 · 95% CI -1.80 to -0.92
  • 0.75 mg Dulaglutide vs Glimepiride · Mixed Models Analysis · p = 0.015 (Treatment comparison for morning (2 hours post-prandial) meal.) · Mean difference (net): -0.55 · 95% CI -0.99 to -0.11
  • 1.5 mg Dulaglutide vs Glimepiride · Mixed Models Analysis · p = <0.001 (Treatment comparison for midday (pre-prandial) meal.) · Mean difference (net): -0.73 · 95% CI -1.10 to -0.36
  • 0.75 mg Dulaglutide vs Glimepiride · Mixed Models Analysis · p = 0.740 (Treatment comparison for midday (pre-prandial) meal.) · Mean difference (net): -0.06 · 95% CI -0.43 to 0.31
  • 1.5 mg Dulaglutide vs Glimepiride · Mixed Models Analysis · p = <0.001 (Treatment comparison of midday (2 hours post-prandial) meal.) · Mean difference (net): -1.56 · 95% CI -1.99 to -1.13
  • 0.75 mg Dulaglutide vs Glimepiride · Mixed Models Analysis · p = <0.001 (Treatment comparison of midday (2 hours post-prandial) meal.) · Mean difference (net): -0.81 · 95% CI -1.24 to -0.39
  • 1.5 mg Dulaglutide vs Glimepiride · Mixed Models Analysis · p = <0.001 (Treatment comparison for evening (pre-prandial) meal.) · Mean difference (net): -0.67 · 95% CI -1.00 to -0.34
  • 0.75 mg Dulaglutide vs Glimepiride · Mixed Models Analysis · p = 0.638 (Treatment comparison for evening (pre-prandial) meal.) · Mean difference (net): -0.08 · 95% CI -0.41 to 0.25
  • 1.5 mg Dulaglutide vs Glimepiride · Mixed Models Analysis · p = <0.001 (Treatment comparison for evening (2 hours post-prandial) meal.) · Mean difference (net): -1.27 · 95% CI -1.68 to -0.87
  • 0.75 mg Dulaglutide vs Glimepiride · Mixed Models Analysis · p = 0.030 (Treatment comparison for evening (2 hours post-prandial) meal.) · Mean difference (net): -0.45 · 95% CI -0.85 to -0.04
  • 1.5 mg Dulaglutide vs Glimepiride · Mixed Models Analysis · p = <0.001 (Treatment comparison for bedtime.) · Mean difference (net): -1.19 · 95% CI -1.56 to -0.82
  • 0.75 mg Dulaglutide vs Glimepiride · Mixed Models Analysis · p = <0.001 (Treatment comparison for bedtime.) · Mean difference (net): -0.66 · 95% CI -1.03 to -0.29
SecondaryRate of Hypoglycemic Episodes

Hypoglycemic episodes are defined as events that are associated with reported signs and symptoms of hypoglycemia and/or documented BG concentrations of ≤70 milligrams per deciliter (mg/dL) (≤3.9 mmol/L). A severe hypoglycemic episode was defined as any hypoglycemic event for which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Nocturnal hypoglycemia is defined as any hypoglycemic event that occurs between bedtime and waking. Log mean rates of total hypoglycemia (per 30 days per participant) are presented and were calculated from negative binomial regression model. The model included country/region, prior medication group, treatment, visit, and treatment-by-visit interaction. The logarithm of days between visits was adjusted as an offset to account for possible unequal duration between visits and between participants.

Time frame:
Baseline through 26 Weeks
Reported as:
Mean · episodes/participant/30 days
Rate of Hypoglycemic Episodes
episodes/participant/30 days1.5 mg Dulaglutide0.75 mg DulaglutideGlimepiride
All Hypoglycemic Episodes0.01 ± 0.0530.01 ± 0.0410.09 ± 0.581
Severe Hypoglycemic EpisodesNA ± NANA ± NANA ± NA
Nocturnal Hypoglycemic Episodes0.00 ± 0.0110.00 ± 0.0100.01 ± 0.057
Statistical analysis
  • 1.5 mg Dulaglutide vs Glimepiride · Negative binomial regression model · p = <0.001 (Treatment comparison for all hypoglycemic episodes.)
  • 0.75 mg Dulaglutide vs Glimepiride · Negative binomial regression model · p = <0.001 (Treatment comparison for all hypoglycemic episodes.)
  • 1.5 mg Dulaglutide vs Glimepiride · Negative binomial regression model · p = 0.008 (Treatment comparison for nocturnal hypoglycemic episodes. Nocturnal hypoglycemic episodes are rounded off to 2 decimal places.)
  • 0.75 mg Dulaglutide vs Glimepiride · Negative binomial regression model · p = 0.006 (Treatment comparison for nocturnal hypoglycemic episodes. Nocturnal hypoglycemic episodes are rounded off to 2 decimal places.)
SecondaryNumber of Participants With Self-Reported Hypoglycemic Episodes

The overall number of participants with self-reported hypoglycemic episodes is presented.

Time frame:
Baseline through 26 Weeks
Reported as:
Number · participants
Number of Participants With Self-Reported Hypoglycemic Episodes
participants1.5 mg Dulaglutide0.75 mg DulaglutideGlimepiride
Number of Participants With Self-Reported Hypoglycemic Episodes14938
Statistical analysis
  • 1.5 mg Dulaglutide vs Glimepiride · Fisher Exact · p = <0.001
  • 0.75 mg Dulaglutide vs Glimepiride · Fisher Exact · p = <0.001
SecondaryChange From Baseline in Homeostasis Model Assessment 2 Steady-state Beta (β) - Cell Function (HOMA2-%B) at 26 Weeks

Change from baseline in HOMA2-%B was assessed by using the homeostasis model assessment (HOMA) to quantify β-cell function. HOMA2-%B is a computer model that uses FBG, insulin, and C-peptide concentrations to estimate steady state β-cell function (%B) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. LS means were calculated using an analysis of covariance (ANCOVA) model with country, baseline, pre-treatment, and treatment as fixed effects.

Time frame:
Baseline, up to 26 Weeks
Reported as:
Least squares mean · percentage of HOMA2-%B
Change From Baseline in Homeostasis Model Assessment 2 Steady-state Beta (β) - Cell Function (HOMA2-%B) at 26 Weeks
percentage of HOMA2-%B1.5 mg Dulaglutide0.75 mg DulaglutideGlimepiride
Insulin-based HOMA-2%B47.40 ± 2.62437.92 ± 2.66430.00 ± 2.591
C-peptide HOMA-2%B41.02 ± 1.94534.57 ± 1.97424.58 ± 1.964
Statistical analysis
  • 1.5 mg Dulaglutide vs Glimepiride · ANCOVA · p = <0.001 · Mean difference (net): 17.41 · 95% CI 11.27 to 23.55
  • 0.75 mg Dulaglutide vs Glimepiride · ANCOVA · p = 0.012 · Mean difference (net): 7.92 · 95% CI 1.78 to 14.06
  • 1.5 mg Dulaglutide vs Glimepiride · ANCOVA · p = <0.001 · Mean difference (net): 16.44 · 95% CI 11.81 to 21.06
  • 0.75 mg Dulaglutide vs Glimepiride · ANCOVA · p = <0.001 · Mean difference (net): 9.99 · 95% CI 5.36 to 14.62
SecondaryChange From Baseline in Homeostasis Model Assessment 2 Insulin Sensitivity - Cell Function (HOMA2-%S) at 26 Weeks

Change from baseline in HOMA2-%S was assessed by using the HOMA to quantify insulin sensitivity. HOMA2-%S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate steady state insulin sensitivity (%S) as a percentage of a normal reference population (normal young adults). The normal reference population was set at 100%. LS means were calculated using an ANCOVA model with country, baseline, pre-treatment, and treatment as fixed effects.

Time frame:
Baseline, up to 26 Weeks
Reported as:
Least squares mean · percentage of HOMA2-%S
Change From Baseline in Homeostasis Model Assessment 2 Insulin Sensitivity - Cell Function (HOMA2-%S) at 26 Weeks
percentage of HOMA2-%S1.5 mg Dulaglutide0.75 mg DulaglutideGlimepiride
Insulin-Based HOMA2-%S-6.85 ± 2.636-10.33 ± 2.662-7.19 ± 2.602
C-Peptide-Based HOMA2-%S-6.44 ± 2.056-11.84 ± 2.082-5.05 ± 2.074
Statistical analysis
  • 1.5 mg Dulaglutide vs Glimepiride · ANCOVA · p = 0.913 · Mean difference (net): 0.34 · 95% CI -5.83 to 6.51
  • 0.75 mg Dulaglutide vs Glimepiride · ANCOVA · p = 0.318 · Mean difference (net): -3.14 · 95% CI -9.30 to 3.03
  • 1.5 mg Dulaglutide vs Glimepiride · ANCOVA · p = 0.576 · Mean difference (net): -1.39 · 95% CI -6.27 to 3.49
  • 0.75 mg Dulaglutide vs Glimepiride · ANCOVA · p = 0.007 · Mean difference (net): -6.79 · 95% CI -11.68 to -1.89
SecondaryChange From Baseline in Pancreatic Enzymes at 26 Weeks

Amylase (total and pancreas-derived) and lipase concentrations were measured.

Time frame:
Baseline, 26 Weeks
Reported as:
Mean · units per liter (u/L)
Change From Baseline in Pancreatic Enzymes at 26 Weeks
units per liter (u/L)1.5 mg Dulaglutide0.75 mg DulaglutideGlimepiride
Total amylase9.29 ± 16.2377.04 ± 13.1283.79 ± 12.538
Pancreas-derived amylase6.19 ± 12.8244.92 ± 8.1232.64 ± 8.218
Lipase10.62 ± 30.0869.28 ± 22.6512.38 ± 22.717
SecondaryChange From Baseline in Serum Calcitonin at 26 Weeks
Time frame:
Baseline, 26 Weeks
Reported as:
Mean · picomoles per liter (pmol/L)
Change From Baseline in Serum Calcitonin at 26 Weeks
picomoles per liter (pmol/L)1.5 mg Dulaglutide0.75 mg DulaglutideGlimepiride
Change From Baseline in Serum Calcitonin at 26 Weeks-0.01 ± 0.318-0.02 ± 0.2980.02 ± 1.193
SecondaryChange From Baseline in Sitting Blood Pressure at 26 Weeks

Sitting systolic blood pressure (SBP) and sitting diastolic blood pressure (DBP) were measured. LS means were calculated using MMRM analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline blood pressure as covariate; and participant as a random effect.

Time frame:
Baseline, 26 Weeks
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change From Baseline in Sitting Blood Pressure at 26 Weeks
millimeters of mercury (mmHg)1.5 mg Dulaglutide0.75 mg DulaglutideGlimepiride
SBP-2.07 ± 0.815-1.88 ± 0.813-0.66 ± 0.804
DBP-0.10 ± 0.535-0.11 ± 0.5340.15 ± 0.526
Statistical analysis
  • 1.5 mg Dulaglutide vs Glimepiride · Mixed Models Analysis · p = 0.180 (Treatment comparison for SBP.)
  • 0.75 mg Dulaglutide vs Glimepiride · Mixed Models Analysis · p = 0.245 (Treatment comparison for SBP.)
  • 1.5 mg Dulaglutide vs Glimepiride · Mixed Models Analysis · p = 0.717 (Treatment comparison for DBP.)
  • 0.75 mg Dulaglutide vs Glimepiride · Mixed Models Analysis · p = 0.619 (Treatment comparison for DBP.)
SecondaryChange From Baseline in Sitting Pulse Rate at 26 Weeks

LS means were calculated using MMRM analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline pulse rate as covariate; and participant as a random effect.

Time frame:
Baseline, 26 Weeks
Reported as:
Least squares mean · beats per minute (bpm)
Change From Baseline in Sitting Pulse Rate at 26 Weeks
beats per minute (bpm)1.5 mg Dulaglutide0.75 mg DulaglutideGlimepiride
Change From Baseline in Sitting Pulse Rate at 26 Weeks3.07 ± 0.5811.24 ± 0.581-0.34 ± 0.572
Statistical analysis
  • 1.5 mg Dulaglutide vs Glimepiride · Mixed Models Analysis · p = <0.001
  • 0.75 mg Dulaglutide vs Glimepiride · Mixed Models Analysis · p = 0.035
SecondaryChange From Baseline in Electrocardiogram (ECG) Parameters, Fridericia Corrected QT (QTcF) Interval and P-R Wave (PR) Interval at 26 Weeks

The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTcF = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and R-R wave (RR), which is the interval between two R waves. PR is the interval between the P wave and the ventricular depolarization wave (QRS) complex.

Time frame:
Baseline, 26 Weeks
Reported as:
Mean · milliseconds (msec)
Change From Baseline in Electrocardiogram (ECG) Parameters, Fridericia Corrected QT (QTcF) Interval and P-R Wave (PR) Interval at 26 Weeks
milliseconds (msec)1.5 mg Dulaglutide0.75 mg DulaglutideGlimepiride
QT interval-6.18 ± 21.469-2.06 ± 19.5491.21 ± 23.021
PR interval3.73 ± 13.4113.29 ± 11.236-0.23 ± 10.184
SecondaryChange From Baseline in Heart Rate From ECG at 26 Weeks
Time frame:
Baseline, 26 Weeks
Reported as:
Mean · bpm
Change From Baseline in Heart Rate From ECG at 26 Weeks
bpm1.5 mg Dulaglutide0.75 mg DulaglutideGlimepiride
Change From Baseline in Heart Rate From ECG at 26 Weeks3.99 ± 8.4591.90 ± 8.0460.44 ± 9.275
SecondaryChange From Baseline in Body Weight at 26 Weeks

LS means were calculated using MMRM analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline body weight as covariate; and participant as a random effect.

Time frame:
Baseline, 26 Weeks
Reported as:
Least squares mean · kilogram (kg)
Change From Baseline in Body Weight at 26 Weeks
kilogram (kg)1.5 mg Dulaglutide0.75 mg DulaglutideGlimepiride
Change From Baseline in Body Weight at 26 Weeks-1.46 ± 0.192-0.77 ± 0.1920.89 ± 0.190
Statistical analysis
  • 1.5 mg Dulaglutide vs Glimepiride · Mixed Models Analysis · p = <0.001
  • 0.75 mg Dulaglutide vs Glimepiride · Mixed Models Analysis · p = <0.001
SecondaryChange From Baseline in Body Mass Index (BMI) at 26 Weeks

BMI is an estimate of body fat based on body weight divided by height squared. LS means were calculated using MMRM analysis adjusting for treatment, country, pre-study therapy stratum, visit, and treatment-by-visit as fixed effects; baseline body weight as covariate; and participant as a random effect.

Time frame:
Baseline, 26 Weeks
Reported as:
Least squares mean · kilograms per meter squared (kg/m^2)
Change From Baseline in Body Mass Index (BMI) at 26 Weeks
kilograms per meter squared (kg/m^2)1.5 mg Dulaglutide0.75 mg DulaglutideGlimepiride
Change From Baseline in Body Mass Index (BMI) at 26 Weeks-0.55 ± 0.070-0.29 ± 0.0700.32 ± 0.069
Statistical analysis
  • 1.5 mg Dulaglutide vs Glimepiride · Mixed Models Analysis · p = <0.001
  • 0.75 mg Dulaglutide vs Glimepiride · Mixed Models Analysis · p = <0.001
SecondaryPercentage of Participants Developing Antibodies to Dulaglutide

Dulaglutide anti-drug antibodies (ADA) were assessed at baseline and 26 weeks. A participant was considered to have treatment-emergent dulaglutide ADA if the participant had at least 1 titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.

Time frame:
Baseline through 26 Weeks
Reported as:
Number · percentage of participants
Percentage of Participants Developing Antibodies to Dulaglutide
percentage of participants1.5 mg Dulaglutide0.75 mg DulaglutideGlimepiride
Percentage of Participants Developing Antibodies to Dulaglutide1784
SecondaryNumber of Participants With Adjudicated Cardiovascular Events

Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs that were adjudicated included myocardial infarction; hospitalization for unstable angina; hospitalization for heart failure; coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention); and cerebrovascular events, including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious AEs regardless of causality, is located in the Reported Adverse Events module.

Time frame:
Baseline through 26 Weeks
Reported as:
Number · number of participants
Number of Participants With Adjudicated Cardiovascular Events
number of participants1.5 mg Dulaglutide0.75 mg DulaglutideGlimepiride
Number of Participants With Adjudicated Cardiovascular Events010
SecondaryNumber of Participants With Adjudicated Pancreatitis

The number of adjudicated (by an independent committee of expert physicians) pancreatic events is summarized at 26 weeks. A summary of serious and other non-serious AEs regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 26 Weeks
Reported as:
Number · participants
Number of Participants With Adjudicated Pancreatitis
participants1.5 mg Dulaglutide0.75 mg DulaglutideGlimepiride
Number of Participants With Adjudicated Pancreatitis751
SecondaryEuropean Quality of Life Questionnaire-5 Dimensions (EQ-5D) Health State Score Responses at 26 Weeks

The EQ-5D questionnaire is a widely used, generic questionnaire that assesses 5 dimensions associated with quality of life (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 possible levels of response: no problem, some problem, and extreme problem. Additional categories of response include ambiguous and missing. The number of participants per each of the 5 response categories is summarized for each of the 5 dimensions.

Time frame:
Week 26
Reported as:
Number · participants
European Quality of Life Questionnaire-5 Dimensions (EQ-5D) Health State Score Responses at 26 Weeks
participants1.5 mg Dulaglutide0.75 mg DulaglutideGlimepiride
Mobility - no problem217218224
Mobility - some problem436
Mobility - extreme problem000
Mobility - ambiguous000
Mobility - missing131
Self-care - no problem221220228
Self-care - some problem012
Self-care - extreme problem000
Self-care - ambiguous000
Self-care - missing131
Usual activities - no problems221219228
Usual activities - some problems022
Usual activities - extreme problems000
Usual activities - ambiguous000
Usual activities - missing131
Pain/Discomfort - no problems198192200
Pain/Discomfort - some problems232829
Pain/Discomfort - extreme problems000
Pain/Discomfort - ambiguous000
Pain/Discomfort - missing131
Anxiety/Depression - no problems208214213
Anxiety/Depression - some problems13717
Anxiety/Depression - extreme problems000
Anxiety/Depression - ambiguous000
Anxiety/Depression - missing131
SecondaryVisual Analog Scale (VAS) Score at 26 Weeks

The EQ-5D questionnaire is a widely used, generic questionnaire that assesses health-related quality of life and consists of a 100-milliliter (mm) visual analog scale (VAS) on which the participant rated their perceived health state on that day from 0-mm (worst imaginable health state) to 100-mm (best imaginable health state).

Time frame:
Week 26
Reported as:
Mean · units on a scale
Visual Analog Scale (VAS) Score at 26 Weeks
units on a scale1.5 mg Dulaglutide0.75 mg DulaglutideGlimepiride
Visual Analog Scale (VAS) Score at 26 Weeks85.72 ± 9.72386.17 ± 10.74485.96 ± 10.938

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1.5 mg Dulaglutide—6/244 (2.5%)165/244 (67.6%)
0.75 mg Dulaglutide—4/248 (1.6%)141/248 (56.9%)
Glimepiride—3/243 (1.2%)137/243 (56.4%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
Event1.5 mg Dulaglutide0.75 mg DulaglutideGlimepiride
Spinal osteoarthritisMusculoskeletal and connective tissue disorders2/2440/2481/243
CataractEye disorders0/2440/2481/243
Cataract diabeticEye disorders0/2440/2481/243
GlaucomaEye disorders0/2440/2481/243
Retinal vein occlusionEye disorders0/2440/2481/243
PneumoniaInfections and infestations0/2440/2481/243
DyslipidaemiaMetabolism and nutrition disorders0/2440/2481/243
HyperhomocysteinaemiaMetabolism and nutrition disorders0/2440/2481/243
Diabetic neuropathyNervous system disorders0/2440/2481/243
Supraventricular tachycardiaCardiac disorders1/2440/2480/243
Most frequent other events
Showing 10 of 234
Most frequent other events
Event1.5 mg Dulaglutide0.75 mg DulaglutideGlimepiride
DiarrhoeaGastrointestinal disorders42/24418/2487/243
HyperlipidaemiaMetabolism and nutrition disorders27/24430/24841/243
NauseaGastrointestinal disorders25/24413/2481/243
VomitingGastrointestinal disorders19/2444/2481/243
Abdominal distensionGastrointestinal disorders16/2446/2485/243
NasopharyngitisInfections and infestations16/24413/24813/243
Lipase increasedInvestigations15/24414/2486/243
Decreased appetiteMetabolism and nutrition disorders15/24413/2481/243
Upper respiratory tract infectionInfections and infestations10/2448/24811/243
DyslipidaemiaMetabolism and nutrition disorders9/2449/24810/243

Baseline characteristics

Baseline characteristics is reported for the modified intent-to-treat population, who are all randomized participants with a baseline glycosylated hemoglobin (HbA1c) measurement, with at least 1 post-baseline HbA1c measurement, and who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)1.5 mg Dulaglutide0.75 mg DulaglutideGlimepirideTotal
Mean52.69 ± 10.75453.79 ± 10.09351.97 ± 10.05252.81 ± 10.317
Sex: Female, Male
Sex: Female, Male(Participants)1.5 mg Dulaglutide0.75 mg DulaglutideGlimepirideTotal
Female105112112329
Male134127130391
Race (NIH/OMB)
Race (NIH/OMB)(Participants)1.5 mg Dulaglutide0.75 mg DulaglutideGlimepirideTotal
American Indian or Alaska Native0000
Asian239239242720
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)1.5 mg Dulaglutide0.75 mg DulaglutideGlimepirideTotal
Taiwan29282986
China184186186556
South Korea26252778
08

Study locations

30 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beijing, 100088, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Changsha, 410011, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chengdu, 610041, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chongqing, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guang Zhou, 510120, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guiyang, 550004, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hangzhou, 310009, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Harbin, 150001, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hefei, 230022, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Huai'An, 223300, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jinan, 250001, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nanjing, 210029, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nanning, 530007, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Qingdao, 266003, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shanghai, 200040, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shenyang, 110004, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shijiazhuang, 050000, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wu Han, 430022, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wuxi, 214023, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Xi'An, 710032, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Xiamen, 361003, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gangwon-Do, 200-722, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jeju Special Self-Governing Pr, 690-767, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Seoul, 134-090, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Changhua, 500, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jhonghe City, 235, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kaohsiung, 824, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Niao Sung Hsiang, 833, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sindian City, 23148, Taiwan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Yong Kung City, 71004, Taiwan
09

References and documents

Publications

  • Kuang J, Zhu J, Liu S, Li Q. Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies. Diabetes Ther. 2020 Oct;11(10):2329-2339. doi: 10.1007/s13300-020-00910-1. Epub 2020 Aug 28. PubMed 32857293 ↗
  • Guo L, Zhang B, Hou J, Zhou Z. Evaluation of Characteristics of Gastrointestinal Adverse Events with Once-Weekly Dulaglutide Treatment in Chinese Patients with Type 2 Diabetes: A Post Hoc Pooled Analysis of Two Randomized Trials. Diabetes Ther. 2020 Aug;11(8):1821-1833. doi: 10.1007/s13300-020-00869-z. Epub 2020 Jul 4. PubMed 32621083 ↗
  • Yu M, Yuan GY, Zhang B, Wu HY, Lv XF. Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis. Diabetes Ther. 2020 May;11(5):1147-1159. doi: 10.1007/s13300-020-00804-2. Epub 2020 Apr 10. PubMed 32277401 ↗
  • Li YM, Zhang LH, Li XJ, Zhang B, Hou JN, Tong NW. Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naive Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1. Diabetes Ther. 2020 May;11(5):1077-1090. doi: 10.1007/s13300-020-00799-w. Epub 2020 Mar 26. PubMed 32219675 ↗
  • Li H, Xu X, Wang J, Kong X, Chen M, Jing T, Zhang Z, Yin G, Liu X, Hu Y, Ye L, Su X, Ma J. A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up. J Diabetes Res. 2019 Apr 30;2019:6423987. doi: 10.1155/2019/6423987. eCollection 2019. PubMed 31183384 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2012
First posted
Jul 19, 2012
Start
Jul 2012
Primary completionActual
Aug 2014
CompletionActual
Aug 2014
Results first posted
Dec 17, 2015
Last update
Sep 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01644500
Responsible party
Sponsor
First posted
Jul 19, 2012
Start date
Jul 2012
Primary completion
Aug 2014
Completion
Aug 2014
Results posted
Dec 17, 2015
Last update
Sep 18, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion